Haleon PLC Sponsored ADR $HLN Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 42.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 292,778 shares of the company’s stock after selling 220,384 shares during the quarter. QRG Capital Management Inc.’s holdings in Haleon were worth $2,626,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 15.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock worth $91,014,000 after purchasing an additional 1,174,813 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Haleon by 6.5% during the second quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock valued at $81,479,000 after purchasing an additional 476,823 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Haleon by 3,031.5% during the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after buying an additional 5,212,711 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in Haleon by 0.7% in the second quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock worth $44,748,000 after buying an additional 29,287 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of Haleon stock opened at $9.84 on Tuesday. The stock has a market cap of $43.82 billion, a PE ratio of 25.23 and a beta of 0.19. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $9.82 and a 200-day simple moving average of $9.60.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft lowered Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.